Share
67 Posts.
lightbulb Created with Sketch. 95
clock Created with Sketch.
06/05/22
02:51
Share
Originally posted by Rich&Poor:
↑
Thank you, Rinnekin for posting the Pro active investor interview video. James has his mojo back with discussion on the release dates of paxalisib trials both interim and final data next month. He discusses demand from the US sophisticated investors for ADS's - At The Market (ATM) share cash equity issuing facility eloquently, using examples of possible liquidity demand for ADS's - ATM when the KZIA share price is maybe double or triple in value, which could be triggered by new regional drug licence agreements, (similar to the Simcere China licence) Possible new paxalisib trial next year for rare childhood cancer AT/RT DIPG - PNOC study recruiting like wildfire with possibility of registration approval with a valuable rare childhood disease voucher attached. GBM AGILE phase 3 registration data available - 2H CY2023. And the list goes on and on. Regards.
Expand
James has his mojo back He never lost his mojo. Others lost their patience.